Bhalla Narinder Pal
SEC insider (Form 3/4/5 filer). CIK 0002109299. Chief Medical Officer at Lexeo Therapeutics, Inc. (LXEO). 5 reported Form 4/5 transactions since Sep 2024; latest on Sep 24, 2026. Located in NEW YORK, NY.
Companies Bhalla Narinder Pal has filed insider reports for
- Lexeo Therapeutics, Inc. (LXEO): Officer, Chief Medical Officer
Bhalla Narinder Pal
CIK: 0002109299
Transaction Breakdown
Open Market Buys (P)0 (0.0%)
High conviction signal
Open Market Sales (S)1 (20.0%)
Position reduction
Option Exercises (M)0 (0.0%)
Derivative conversions
Awards (A)4 (80.0%)
Compensation grants
Other (G, F, J, C, D, …)0 (0.0%)
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
LXEO
Lexeo Therapeutics, Inc.
Officer
Discretionary Trading P&L
Holdings
Transaction History (5 total)
- Sep 24, 2026LXEO
Lexeo Therapeutics, Inc.
AwardDirectStock Option (right to buy)
54.8K shares- - Sep 14, 2026LXEO
Lexeo Therapeutics, Inc.
AwardDirect2.7K shares at avg. $3.58$10K - Jul 1, 2026LXEO
Lexeo Therapeutics, Inc.
SaleDirect22.3K shares at avg. $4.42$99K - Jun 29, 2026LXEO
Lexeo Therapeutics, Inc.
AwardDirect55K shares- - Feb 13, 2026LXEO
Lexeo Therapeutics, Inc.
AwardDirect49.5K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Sep 24, 2026 | LXEO Lexeo Therapeutics, Inc. | Award Stock Option (right to buy) | 54,750 | - | - | Direct |
| Sep 14, 2026 | LXEO Lexeo Therapeutics, Inc. | Award | 2,714 | $3.58 | $9,713 | Direct |
| Jul 1, 2026 | LXEO Lexeo Therapeutics, Inc. | Sale | 22,306 | $4.42 | $98,593 | Direct |
| Jun 29, 2026 | LXEO Lexeo Therapeutics, Inc. | Award | 55,000 | - | $0 | Direct |
| Feb 13, 2026 | LXEO Lexeo Therapeutics, Inc. | Award | 49,500 | - | $0 | Direct |
1-5 of 5 transactions